Drugs / IPV-Al SSI
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02347423 | Feb → Sep 2015 | poliomyelitis | Statens Serum Institut | Completed | Met primary |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT03671616 | May → Oct 2018 | poliomyelitis | Statens Serum Institut | Completed | No outcome recorded |
| Phase 3 | NCT03025750 | Jan → Nov 2017 | poliomyelitis | Statens Serum Institut | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-03-19 | AJ Vaccines A/S | AJ Vaccines successfully completes two phase III trials of its new low-dose IPV-Al vaccine ajvaccines.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPV-Al SSI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02347423 ↗ |
| Known as | IPV-Al | “three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a...” PMID 28454674 ↗ Apr 20171“The results presented here demonstrate non-inferiority of a reduced-dose, aluminium hydroxide-adjuvanted IPV (IPV-Al) to standard IPV.” PMID 32273184 ↗ Apr 2020 |
| Modality | Vaccine | “three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al)” PMID 28454674 ↗ Apr 2017 |
| Route | Intramuscular | “receive one of four IPV formulations (three-times reduced dose [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly...” PMID 28454674 ↗ Apr 2017 |